CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04913337
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:09.806684+00:00
Published At: 2024-10-02T00:00:00+00:00
Record Updated At: 2024-10-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Mesothelioma", "Glioblastoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Melanoma", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endocervical Cancer", "Colorectal Cancer", "Esophageal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-10-02"
protocolSection.identificationModule.nctId: "NCT04913337"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.